

# High-Efficiency Production of the Bisabolene from Waste Cooking Oil By Metabolically Engineered *Yarrowia Lipolytica*

**Yakun Zhao**

Tianjin University of Technology School of Material Science and Engineering

**Kun Zhu**

Tianjin University of Science and Technology

**Jian Li**

Tianjin University of Science and Technology

**Yu Zhao**

Tianjin University of Science and Technology

**Shenglong Li**

Tianjin University of Science and Technology

**Cuiying Zhang**

Tianjin University of Science and Technology

**Dongguang Xiao**

Tianjin University of Science and Technology

**Aiqun Yu** (✉ [yuaiqun@tust.edu.cn](mailto:yuaiqun@tust.edu.cn))

Tianjin University of Science and Technology <https://orcid.org/0000-0002-2488-8636>

---

## Research

**Keywords:** *Y. lipolytica*, bisabolene, mevalonate pathway, metabolic engineering, fermentation optimization, waste cooking oil

**Posted Date:** September 8th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-71409/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Microbial Biotechnology on February 19th, 2021. See the published version at <https://doi.org/10.1111/1751-7915.13768>.

# Abstract

**Background:** The natural plant product bisabolene serves as a precursor for the production of a wide range of industrially relevant chemicals. However, the low abundance of bisabolene in plants renders their isolation from plant sources economically inviable. Therefore, creation of microbial cell factories for bisabolene production supported by synthetic biology and metabolic engineering strategies presents a more competitive and environmentally sustainable method for industrial production of bisabolene.

**Results:** In this proof-of-principle study, for the first time, we engineered the oleaginous yeast *Yarrowia lipolytica* to produce  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene through heterologous expression of the  $\alpha$ -bisabolene synthase from *Abies grandis*, the  $\beta$ -bisabolene synthase gene from *Zingiber officinale* and the  $\gamma$ -bisabolene synthase gene from *Helianthus annuus*, respectively. Subsequently, metabolic engineering approaches, including overexpression of the endogenous mevalonate pathway genes and introduction of heterologous multidrug efflux transporters, were employed to improve bisabolene production. Furthermore, the fermentation conditions were optimized to maximize *de novo* bisabolene production by the engineered *Y. lipolytica* strains from glucose. Our engineering strategies have led to engineered *Y. lipolytica* strains that produce 282.6 mg/L  $\alpha$ -bisabolene, 48.3 mg/L  $\beta$ -bisabolene and 5.3 mg/L  $\gamma$ -bisabolene. Finally, we explored the potential of the engineered *Y. lipolytica* strains for bisabolene production from waste cooking oil. The results showed that  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene could be produced at the respective titers of 973.0 mg/L, 68.2 mg/L, 20.2 mg/L in shake flasks. These titers correspond to 2433-fold, 340-fold and 404-fold enhancement in bisabolene production, respectively, over the parent strain.

**Conclusions:** To our knowledge, this is the first report of bisabolene production in *Y. lipolytica*. These findings provide valuable insights into the engineering of *Y. lipolytica* for higher-level production of bisabolene and its utilization in converting waste cooking oil into various industrially valuable products.

## 1. Background

Bisabolene (C<sub>15</sub>H<sub>24</sub>) is the simplest monocyclic sesquiterpene and also a bioactive compound that commonly exists in natural plant essential oils. It has three structural isomers, namely  $\alpha$ -bisabolene,  $\beta$ -bisabolene, and  $\gamma$ -bisabolene, and each isomer has distinctly different properties and applications. Currently, the plant terpenoid bisabolene has a wide range of applications in cosmetic, chemical, pharmaceutical and nutraceutical industries [1, 2]. Traditionally, bisabolene is extensively used as a high-value fragrance and flavour compound in many industries because bisabolene has highly pleasant fruity and balsamic aroma [3]. For example,  $\beta$ -bisabolene has an odor similar to sesame oil and thus can be used as a food flavoring. Furthermore, bisabolene are being investigated as anti-inflammatory and anti-cancer agents and thus would be of great benefit to the medical community [4]. In addition, bisabolene could also serve as an essential starting material for the synthesis of various commercially valuable products [1, 2].

At present, the industrial production of bisabolene is mostly achieved by direct extraction from plant tissues. However, this method has many disadvantages, such as limited raw material source, low yield of the product and complicated separation steps [5]. Likewise, chemical syntheses of bisabolene suffer from the complexity of the production equipment and low conversion rate of raw materials [6]. These processes are also energy intensive and can cause environmental issues. As a result, there is an ever-increasing demand to develop alternative and renewable route to bisabolene. Among the alternative approaches, biosynthesizing bisabolene in microbial cell

factories generated by metabolic engineering and synthetic biology is becoming a highly promising strategy that can overcome the aforementioned bottleneck, making bisabolene production more sustainable and environmentally friendly.

The industrial microbe *Yarrowia lipolytica* is an unconventional oleaginous yeast, which was classified by the US Food and Drug Administration as generally regarded as safe (GRAS) [7]. One of the distinguishing metabolic features of *Y. lipolytica* is that it is capable of efficiently utilizing a variety of low-cost hydrophobic substrates for growth [8]. In recent years, *Y. lipolytica* has demonstrated its versatility and importance as a production host platform by its successful application for a wide range of purposes in metabolic engineering and synthetic biology [9–11]. *Y. lipolytica* has been particularly considered as an attractive host platform for the production of terpenes because its endogenous cytosolic mevalonate (MVA) pathway can give rise to geranyl diphosphate (GPP), farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which are the direct substrates for the biosynthesis of monoterpenes, sesquiterpenes and diterpenes respectively. To date, several plant terpenes have been successfully produced in this engineered yeast. These mainly include the monoterpenes limonene [12, 13] and linalool [14], the sesquiterpene farnesene [15], the triterpene betulinic acid [16], and the tetraterpene  $\beta$ -carotene [17, 18] and lycopene [19, 20].

In this study, we report the engineering of *Y. lipolytica* for the overproduction of bisabolene (Fig. 1A). First, we engineered *Y. lipolytica* to heterologously express the selected genes of  $\alpha$ -bisabolene synthase,  $\beta$ -bisabolene synthase and  $\gamma$ -bisabolene synthase to produce the corresponding bisabolene from FPP. To our knowledge, this is the first report of bisabolene production in *Y. lipolytica*. Second, the influence of overexpressing genes involved in the MVA pathway on bisabolene production was examined. Third, we demonstrated that expression of heterologous efflux pumps could lead to increased bisabolene production. Finally, the potential of using waste cooking oil as the carbon source for bisabolene production was investigated with the engineered *Y. lipolytica* strains. The outcome of this work shows that our engineered *Y. lipolytica* can serve as a platform strain for future metabolic engineering efforts to biosynthesize valuable bisabolene-derived chemicals.

## 2. Results And Discussion

### 2.1. Production of bisabolene in *Y. lipolytica* by introduction of plant bisabolene synthases

In nature, bisabolene is biosynthesized in plants by bisabolene synthases. Specifically, FPP is produced by the methylerythritol 4-phosphate (MEP) pathway and converted in the final step of the bisabolene biosynthesis pathway by three different bisabolene synthases into  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene (Fig. 1B). Although the MEP pathway is absent in *Y. lipolytica*, the yeast has a native MVA pathway that could supply FPP as substrate (Fig. 1A). Therefore, to construct a complete bisabolene biosynthetic pathway in *Y. lipolytica*, the codon-optimized genes of  $\alpha$ -bisabolene synthase ( $\alpha$ -BS) from *Abies grandis*, the  $\beta$ -bisabolene synthase ( $\beta$ -BS) from *Zingiber officinale* and the  $\gamma$ -bisabolene synthase ( $\gamma$ -BS) from *Helianthus annuus*, were synthesized and subsequently introduced into the *Y. lipolytica* Po1g KU70 $\Delta$  strain (Fig. 1A). We selected these three enzyme candidates because they have been successfully applied to produce  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene. The selected  $\alpha$ -BS and  $\beta$ -BS have already been functionally expressed in *Escherichia coli* [21, 22] and the  $\gamma$ -BS chosen has already been functionally expressed in *Saccharomyces cerevisiae* [23]. Furthermore, because the rate of precise homologous recombination in the *Y. lipolytica* Po1g KU70 $\Delta$  strain is much higher than that of the parent

strain Po1g, we chose to use Po1g KU70 $\Delta$  as the starting host strain to facilitate genomic manipulation [24]. Upon integration of the genes of the bisabolene synthases individually into the genome of *Y. lipolytica* for overexpression, the desired compounds were successfully biosynthesized in the recombinant strains. Consequently, the resulting engineered strains Po1g K $\alpha$ BS produced 0.4 mg/L of  $\alpha$ -bisabolene (Fig. 2), Po1g K $\beta$ BS produced  $\beta$ -bisabolene at 0.2 mg/L (Fig. 3) and Po1g K $\gamma$ BS produced 0.05 mg/L of  $\gamma$ -bisabolene (Fig. 4).

## 2.2. Metabolic engineering of the MVA pathways to improve bisabolene production in *Y. lipolytica*

With the successful synthesis of bisabolene, we set out to improve the *Y. lipolytica* production of bisabolene via metabolic engineering of the MVA pathway. In the optimization attempt, the genes involved in the MVA pathway were overexpressed to increase the flux towards bisabolene. Ten genes consisting of *ACOAT1*, *ACOAT2*, *HMGS*, *HMGR*, *MK*, *PMK*, *PMVADO*, *IPPD1*, *GGPPS* and *FPFS* were overexpressed respectively (Fig. 1A), and their effects on the overproduction of bisabolene were examined to determine the rate limiting enzyme for bisabolene synthesis in the MVA pathway of *Y. lipolytica*. Thus, a further 30 strains that individually overexpress the ten endogenous genes in the MVA pathway of *Y. lipolytica* were generated based on Po1g K $\alpha$ BS, Po1g K $\beta$ BS and Po1g K $\gamma$ BS. All genes were integrated into the chromosome and under the control of the strong constitutive promoter hp4d.

Individual overexpression of the selected genes does not have any adverse effect on cell growth (Additional file 1: Figure S1). Among them, the highest titers were achieved in the *HMGR*-overexpressing strains Po1g K $\alpha$ HR (Fig. 2), Po1g K $\beta$ HR (Fig. 3), Po1g K $\gamma$ HR (Fig. 4), reaching  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene titers of 100.2 mg/L, 5.7 mg/L, and 3.6 mg/L, respectively, after 5 days of culture. These titers correspond to 251-fold, 29-fold and 72-fold enhancement in  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene production, respectively, over the control strains expressing only the respective bisabolene synthases. This result indicates that overexpression of the endogenous 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase of *Y. lipolytica*, encoded by *HMGR*, is a very efficient way to improve bisabolene biosynthesis in *Y. lipolytica*. This observation is consistent with several other studies where the HMG-CoA reductase has already been demonstrated to be the key rate-limiting enzyme in the production of various molecules derived from mevalonate via the mevalonate pathway [25–29]. Therefore, the engineered strains Po1g K $\alpha$ HR, Po1g K $\beta$ HR, and Po1g K $\gamma$ HR were used for subsequent engineering efforts to boost bisabolene production.

## 2.3. Heterologous expression of two efflux pumps for further enhancement of bisabolene production in *Y. lipolytica*

Product toxicity is a common problem in strain engineering for biotechnology applications. Small lipophilic products diffuse easily into and through eukaryotic cell membranes, interact with membranes and membrane-bound enzymes, and can also change membrane fluidity and ultrastructure [30–32]. Otherwise, they can also cause fungal cells to swell, shrink and vacuolize [33]. In metabolic engineering, many high-value target compounds, including lipophilic molecules such as bisabolene, are heterologous and toxic to microorganisms. When designing and engineering metabolic pathways for compound production, undesirable trade-offs could be introduced because the engineered microorganism must balance production against survival. Cellular export systems, such as efflux pumps, provide a direct mechanism for reducing product toxicity. Studies on ethanol production have shown that alleviating toxicity is necessary to maintain and maximize its production [34, 35].

Effluxing of the compounds produced through metabolic engineering to the extracellular environment is beneficial to the cell factory. Accelerated efflux can alleviate the toxicity associated with the compounds produced and simplify the recovery of target compounds. It has been reported that the use of transport proteins in engineering microorganisms can improve the efficiency of efflux, and the addition of efflux pumps have proved to successfully increase the production of target compounds [36–38]. Furthermore, regardless of toxicity, effective efflux pumps can alleviate the inhibition of metabolic pathway enzymes by the products, thereby enhancing the bioproduction of target compounds [39, 40]. With improving production levels, efflux pumps may play an increasingly essential role in enhancing tolerance and production [41]. While microorganisms have several strategies for addressing toxicity [42, 43], we herein focus on the utilization of efflux pumps, a class of membrane transporters that uses proton motive force or ATP hydrolysis to export toxins from *Y. lipolytica* cells and thus enhance tolerance to and production of target compounds [44, 45].

For bisabolene extrusion, we selected two transporter candidates. The first is a resistance-nodulation-cell division (RND) family efflux pump from *Escherichia coli*, namely AcrB, because it has been reported that the overexpression of this efflux pump resulted in a 1.5-fold increase in limonene production in the engineered *E. coli* [41]. Furthermore, overexpression of this efflux pump also showed an increased tolerance to  $\alpha$ -bisabolene in *E. coli* [41], indicating substrate recognition by AcrB. As the most important part of the AcrAB-TolC system, to our knowledge, this is the first report of AcrB expression in fungi. The second efflux pump we chose is ABC-G1 from *Grosmannia clavigera*, which is a member of the ATP-binding cassette (ABC) transporter superfamily. This superfamily is widely present in all five kingdoms of life [46] and they share a conserved structural architecture and specifically import or export a wide variety of molecules and ions across cellular membranes [47]. The broad poly-specificity of ABC transporters in general led us to hypothesize that they could be used to recognize certain terpene molecules and achieve their secretion out of the cell. There is considerable evidence that a wide range of extremely lipophilic molecules can be transported by ABC transporters [48] and heterologous expression of ABC-G1 from *Grosmannia clavigera* in *S. cerevisiae* has been shown to increase tolerance to monoterpenes [49].

To evaluate the effects of the selected transporters on bisabolene production, we heterologously expressed AcrB and ABC-G1 using the constitutive promoter hp4d in *Y. lipolytica* Po1g K $\alpha$ HR, Po1g K $\beta$ HR, and Po1g K $\gamma$ HR strains, respectively. The final engineered strains Po1g K $\alpha$ BS-AcrB, Po1g K $\beta$ BS-AcrB and Po1g K $\gamma$ BS-AcrB produced 274.4 mg/L of  $\alpha$ -bisabolene (Fig. 5), 48.3 mg/L of  $\beta$ -bisabolene (Fig. 6) and 5.3 mg/L of  $\gamma$ -bisabolene (Fig. 7), respectively. These results correspond to 2.7-fold, 8.5-fold and 1.2-fold improvement in  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene titers, respectively, over the respective engineered strains (Po1g K $\alpha$ HR, Po1g K $\beta$ HR, and Po1g K $\gamma$ HR). The engineered strains Po1g K $\alpha$ BS-ABCG1, Po1g K $\beta$ BS-ABCG1 and K $\gamma$ BS-ABCG1, which overexpressed ABC-G1, yielded titers of 282.6 mg/L, 23.6 mg/L and 4.3 mg/L for  $\alpha$ -bisabolene (Fig. 5),  $\beta$ -bisabolene (Fig. 6) and  $\gamma$ -bisabolene (Fig. 7), representing a 2.8-fold, 4.1-fold, 1.5-fold increase in titer as compared with the control strains (Po1g K $\alpha$ HR, Po1g K $\beta$ HR, and Po1g K $\gamma$ HR), respectively. These results validate our hypothesis that the expression of heterologous efflux pumps can boost the production of the different bisabolenes. However, this study only demonstrates the efficacies of the two efflux pumps in improving bisabolene production. Future efforts could be invested in understanding the exact substrate binding and transport mechanisms of the two efflux pumps through structural studies, and subsequent engineering for more efficient and specific efflux pumps for applications in bisabolene production.

## 2.4. Using WCO as the carbon source for bisabolene production in the engineered *Y. lipolytica*

Current industrial and domestic practices lead to an excessive production of various low-value or negative-cost byproducts and/or crude oil wastes, which may have adverse effects on the environment and human health due to the presence of undesired substances. For example, waste cooking oils (WCO) mainly refers to vegetable oils used at high temperatures in food frying, mixed in kitchen waste and oily wastewater directly discharged into the sewer. Based on the data that 4.1 kg WCO is generated per person per year [50], it is estimated that the current global annual output of WCO is about 29 million tons [51]. Many developed countries have formulated a set of rules that aim to achieve WCO recycling through proper permit transportation, handling and processing. The collected WCO is mainly used as an ingredient in animal feed or as a raw material for biodiesel production. However, WCO still contains undesired substances that could be transferred to humans through the food chain and, for that reason, in the European Union has strictly prohibited the recycling of WCO for animal feedstock [52]. Additionally, the presence of polar compounds and impurities, and high free fatty acids and water content of WCO might interfere with the biodiesel production and decrease the final quality.

In view of the limitations in using WCO in animal feed and biodiesel production, an alternative approach to recycle WCO is to utilize it as a fermentation media component for the production of value-added compounds by microorganisms. *Y. lipolytica* is well-known for its capacity to produce biotechnologically valuable compounds from fatty substrates and from agro-industrial wastes such as olive mill wastewater and crude glycerol [53, 54]. The availability of considerable amounts of WCO at low cost are attractive for ensuring the economic viability of the bioprocesses, while concurrently reducing major environmental issues.

Our group have previously investigated the potential use of WCO as the carbon source for limonene production using engineered *Y. lipolytica* strains. Therefore, we postulate that WCO can also be used as the sole carbon source for bisabolene production in the engineered *Y. lipolytica* constructed in this study. To verify this hypothesis, the strains Po1g K $\alpha$ BS-AcrB, Po1g K $\beta$ BS-AcrB, Po1g K $\gamma$ BS-AcrB, Po1g K $\alpha$ BS-ABCG1, Po1g K $\beta$ BS-ABCG1 and K $\gamma$ BS-ABCG1 were cultured by feeding 1.18% (w/v) WCO as the carbon source instead of 2% glucose with the same number of carbon units (information on fatty acid composition of the WCO can be found in Additional file 1: Table S1). The results show that  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene were successfully produced utilizing WCO as the sole carbon source. The strain Po1g K $\alpha$ BS-AcrB achieved a titer of 149.9 mg/L  $\alpha$ -bisabolene (Fig. 5), and titers of 11.7 and 3.7 mg/L for  $\beta$ -bisabolene and  $\gamma$ -bisabolene were attained by Po1g K $\beta$ BS-AcrB (Fig. 6) and Po1g K $\gamma$ BS-AcrB (Fig. 7), respectively. The strains Po1g K $\alpha$ BS-ABCG1, Po1g K $\beta$ BS-ABCG1 and K $\gamma$ BS-ABCG1 produced 157.8 mg/L of  $\alpha$ -bisabolene (Fig. 5), 20.9 mg/L of  $\beta$ -bisabolene (Fig. 6) and 3.6 mg/L of  $\gamma$ -bisabolene (Fig. 7), respectively. The OD<sub>600</sub> achieved by feeding 1.18% WCO was significantly higher than that with 2% glucose (Additional file 1: Fig. S3), demonstrating that our engineered bisabolene-producing *Y. lipolytica* strains can grow very efficiently and robustly on WCO as the sole carbon source. However, the titers of  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene achieved in WCO medium declined compared to YPD medium, which contains glucose as the carbon source. This result can be attributed to the sub-optimal cultivation parameters (e.g., concentration of ions, pH and dissolved oxygen level) for bisabolene accumulation of the engineered *Y. lipolytica* strains in this original culture. Therefore, further optimization is required to overcome these hurdles. The outcome of this study suggests that our engineered *Y. lipolytica* strains can serve as a platform strain for future metabolic engineering efforts to biosynthesize bisabolene and valuable bisabolene-derived chemicals from WCO.

## 2.5 Adding magnesium ion further enhances bisabolene production

Metal ions are important factors affecting the growth of and metabolite biosynthesis in microorganisms. They participate in many biological processes, including regulating enzyme activity, maintaining the stability of biological macromolecules and cell structures, regulating the balance of cell osmotic pressure, and controlling the redox potential of cells [55]. The level of metal ions can also affect the functions of transcription factors, and have certain impact on the growth microenvironment of cells [56].

Among the metal ions, magnesium ion is a cofactor of several important enzymes, including pyruvate decarboxylase, pyruvate kinase, hexokinase, phosphofructokinase, glucose-6-phosphate dehydrogenase, citrate lyase and isocitrate dehydrogenase. These enzymes play essential roles in regulating glycolysis, respiration, oxidative phosphorylation and other processes. For oleaginous microorganisms such as *Y. lipolytica*, magnesium ions can bind to the key enzymes in lipid synthesis by affecting the structural integrity of the enzymes. Jernejc et al. [57] added magnesium ions to *Aspergillus niger* and found that the activity of malic enzyme was increased, thereby increasing the formation of reducing power (NADPH). Previously, it was also proven that the addition of  $Mg^{2+}$  has great influence on fermentation performance of oleaginous microorganisms.

Previously, our group has determined that the addition of  $Mg^{2+}$  could effectively improve the production of d-limonene and l-limonene in the engineered *Y. lipolytica*. In addition, the optimal fermentation parameters for limonene production by the *Y. lipolytica* strains [13], that is, a temperature of 20°C, a rotation speed of 250 rpm, pH 5.74 and 0.2%  $Mg^{2+}$ , were already established. These conditions were applied in a typical batch fermentation of the strains overexpressing the ABC-G1 pump, which resulted in the highest production of 973.1 mg/L of  $\alpha$ -bisabolene (Fig. 5), 68.2 mg/L of  $\beta$ -bisabolene (Fig. 6) and 20.2 mg/L of  $\gamma$ -bisabolene (Fig. 7), representing 2433-, 341- and 404-fold increase over that of the starting strain, respectively. Similarly, the strains overexpressing the Acrb pump were fermented and the titers improved to varying degrees.  $\alpha$ -Bisabolene production increased 713-fold to achieve a titer of 285.2 mg/L,  $\beta$ -bisabolene production increased 297-fold to achieve a titer of 59.3 mg/L and  $\gamma$ -bisabolene production increased 222-fold achieve a titer of 11.1 mg/L as shown in Figs. 5–7. Thus, here we demonstrated that addition of  $Mg^{2+}$  could also lead to increased titers of bisabolene in the engineered *Y. lipolytica*, which is similar to the case of limonene [13]. In future work, more studies will be needed for better understanding of mechanism behind the beneficial effect of  $Mg^{2+}$  on the production of both bisabolene and limonene in *Y. lipolytica*.

### 3. Conclusion

Bisabolene is in great demand due to its wide range of industrial applications. The metabolic engineering of microorganisms provides a platform for the effective production of these valuable compounds. Here, we used metabolic engineering tools to construct a new pathway in *Y. lipolytica* to enzymatically convert the abundant acetyl-CoA pool in the oleaginous yeast host into  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene. To our knowledge, this is the first report of bisabolene production in *Y. lipolytica*. After that, we overexpressed efflux pumps and proved that it correlated with a moderate increase in the production of bisabolene. Subsequently, we investigated the potential of our engineered bisabolene-producing *Y. lipolytica* strains in using WCO to produce bisabolene. In addition, we also found that the supplementation of  $Mg^{2+}$  can greatly increase the titer of bisabolene in the engineered *Y. lipolytica* strains. Finally, the highest titers of  $\alpha$ -bisabolene,  $\beta$ -bisabolene, and  $\gamma$ -bisabolene achieved from WCO in the engineered *Y. lipolytica* strains were 973.1 mg/L for  $\alpha$ -bisabolene, 68.2 mg/L for  $\beta$ -bisabolene and 20.2 mg/L for  $\gamma$ -bisabolene. These titers correspond to 2433-fold, 340-fold and 404-fold enhancement in

bisabolene production, respectively, over the starting strain. These results demonstrate the efficacy of the combinatorial engineering strategies applied for the production of bisabolene in *Y. lipolytica* in this study.

To date, there are several studies on successful production of bisabolene by metabolic engineering of microbes (Table 1). Compared to the available data from previous studies, the final titer of  $\alpha$ -bisabolene achieved in *Y. lipolytica* is comparable to the highest reported titer of bisabolene in other microbial hosts. Importantly, the production of  $\beta$ -bisabolene and  $\gamma$ -bisabolene was reported for the first time in the engineered microbes. It is expected that more successful examples of microbial bisabolene production will emerge through strain development coupled with bioprocess engineering.



Table 1  
Bisabolene production in the metabolically engineered microbial hosts

Host	Product	Titer	Yield	Productivity	Strategy	Reference
<i>E.coli</i>	$\alpha$ -bisabolene	912 mg/L	182.4 mg/g glucose	12.49 mg/L/h	The heterologous codon-optimized version of the highest $\alpha$ -bisabolene synthase gene <i>Ag1</i> from <i>A. grandis</i> was co-expressed with four homologous codon-optimized genes <i>tHMGR</i> , <i>HMGS</i> , <i>MK</i> and <i>PMK</i> involved in the MVA pathway from <i>S. cerevisiae</i> under control of a strong promoter <i>P<sub>trc</sub></i> .	[1]
	bisabolene	1.1 g/L	-	15.28 mg/L/h	Inducer-free bisabolene production was achieved by expressing LuxR/LuxI effector-regulator proteins and using <i>P<sub>luxI</sub></i> responsive promoter to drive target biosynthesis pathway with a QS system.	[58]

Host	Product	Titer	Yield	Productivity	Strategy	Reference
<i>S. cerevisiae</i>	$\alpha$ -bisabolene	994 mg/L	-	10.35 mg/L/h	The heterologous codon-optimized version of the highest $\alpha$ -bisabolene synthase gene <i>Ag1</i> from <i>A. grandis</i> was co-expressed with the truncated HMG-CoA reductase (tHMGR), the FPP synthase (Erg20), and the global transcription regulator of the sterol pathway <i>upc2-1</i> and the squalene synthase (Erg9) was downregulated.	[1]
<i>Synechococcus</i> sp. PCC 7002	$\alpha$ -bisabolene	0.6 mg/L	-	6.25 $\mu$ g/L/h	The heterologous <i>A. grandis</i> $\alpha$ -bisabolene synthase gene <i>Ag1</i> was expressed.	[2]
<i>Synechocystis</i> sp. PCC 6803	$\alpha$ -bisabolene	22.2 mg/L	-	0.03 mg/L/h	Improving heterologous protein expression in <i>Synechocystis</i> sp. PCC 6803 by combining RBS calculator and codon optimizations under light condition.	[59]
<i>Chlamydomonas reinhardtii</i>	$\alpha$ -bisabolene	11.0 $\pm$ 0.5 mg/L	-	0.07 mg/L/h	Combining sequential enzyme loading and amiRNA knock-down from four separate genetic constructs and using different carbon and light regimes.	[60]

Host	Product	Titer	Yield	Productivity	Strategy	Reference
<i>Rhodospiridium toruloides</i>	bisabolene	680 mg/L	-	5.04 mg/L/h	Growing in corn stover hydrolysates prepared by two different pretreatment methods, one using a novel biocompatible ionic liquid (IL) choline $\alpha$ -ketoglutarate at bench scale, and the other using an alkaline pretreatment in a high-gravity fed-batch bioreactor.	[61]

As described above, this study shows that bisabolene can be efficiently produced by employing metabolically engineered *Y. lipolytica*. Notably, we demonstrated that the engineered *Y. lipolytica* strains are highly promising microbial platforms for converting WCO into the valuable sesquiterpene and its derivatives, which will bring major breakthroughs to waste conversion and the biochemical industry. We conclude that metabolic engineering will continue to play key roles in developing such economically competitive bioprocesses. However, *Y. lipolytica* as a platform with great potential in converting WCO into bisabolene needs to be further engineered to obtain higher production of bisabolene to realize full-scale commercialization and industrialization. In our future research, metabolic engineering strategies for further reinforcing the metabolic flux of MVA pathway toward FPP, reducing the flux of competing pathways and discovery or engineering of bisabolene synthase with improved catalytic activity could be performed to enhance bisabolene production in engineered *Y. lipolytica*.

## 4. Materials And Methods

All chemicals, solvents, and media components were purchased and used without modification. Pml  $\square$ , Kpn  $\square$ , Spe  $\square$ , Nru  $\square$  and Hpa  $\square$  were purchased from New England Biolabs (Beijing, China), ClonExpress  $\text{\textcircled{R}}$  one step cloning kit, 2  $\times$  Rapid taq master mix and 2  $\times$  Phanta  $\text{\textcircled{R}}$  max master mix were purchased from Vazyme Biotech Co., Ltd. (Nanjing, China), tryptone and yeast extract were purchased from Thermo Scientific Oxoid Microbiology Products (Basingstoke, England), n-dodecane was purchased from Aladdin  $\text{\textcircled{R}}$  (Shanghai, China), bisabolenes were purchased from Sigma-Aldrich (Shanghai, China), or DNA salmon sperm, plasmid eExtraction mini kits and DNA purification kits were purchased from Solarbio life sciences (Beijing, China). *E. coli* DH5 $\alpha$  was used for plasmid construction and amplification and *E. coli* strains were routinely cultured in LB medium supplemented with 100  $\mu$ g/mL of ampicillin at 37  $^{\circ}$ C. *Y. lipolytica* Po1g KU70 $\Delta$  was used as the base strain in this study. Routine cultivation of *Y. lipolytica* strains was carried out at 30  $^{\circ}$ C in YPD medium. In experiments employing WCO as the carbon source, 2% glucose was removed and replaced with appropriate concentrations of WCO. WCO was collected from a local kitchen. The growth medium was also supplemented with Tween-80 when WCO was used as the carbon source. All of the recombinant plasmids were constructed using the One Step Cloning Kit from

Vazyme Biotech Co., Ltd (Nanjing, China). Plasmids used in this study are listed in Table 1 and strains are listed in Table 2. PCR primers used in this study were synthesized by Genewiz (Jiangsu, China) and listed in Table S1.

Table 2  
Plasmids used in this study

Plasmid	Features	Reference
pYLEX1	<i>Y. lipolytica</i> -integrative plasmid, P <sub>hp4d</sub> -T <sub>XPR2</sub> , LEU2	[62]
pYLaBS	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , LEU2	This study
pYLβBS	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , LEU2	This study
pYLYBS	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , LEU2	This study
pYLA1	P <sub>hp4d</sub> -A1-T <sub>XPR2</sub> , LEU2	This study
pYLA2	P <sub>hp4d</sub> -A2-T <sub>XPR2</sub> , LEU2	This study
pYLHS	P <sub>hp4d</sub> -HS-T <sub>XPR2</sub> , LEU2	This study
pYLHR	P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , LEU2	This study
pYLMK	P <sub>hp4d</sub> -MK-T <sub>XPR2</sub> , LEU2	This study
pYLPK	P <sub>hp4d</sub> -PK-T <sub>XPR2</sub> , LEU2	This study
pYLPD	P <sub>hp4d</sub> -PD-T <sub>XPR2</sub> , LEU2	This study
pYLIDI	P <sub>hp4d</sub> -IDI-T <sub>XPR2</sub> , LEU2	This study
pYLGS	P <sub>hp4d</sub> -GS-T <sub>XPR2</sub> , LEU2	This study
pYLFS	P <sub>hp4d</sub> -FS-T <sub>XPR2</sub> , LEU2	This study
pYLaA1	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A1-T <sub>XPR2</sub> , LEU2	This study
PYLaA2	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A2-T <sub>XPR2</sub> , LEU2	This study
pYLaHS	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HS-T <sub>XPR2</sub> , LEU2	This study
pYLaHR	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , LEU2	This study
pYLaMK	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -MK-T <sub>XPR2</sub> , LEU2	This study
pYLaPK	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PK-T <sub>XPR2</sub> , LEU2	This study
pYLaPD	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PD-T <sub>XPR2</sub> , LEU2	This study
pYLaIDI	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -IDI-T <sub>XPR2</sub> , LEU2	This study
pYLaGS	P <sub>hp4d</sub> -dLS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -GS-T <sub>XPR2</sub> , LEU2	This study
pYLaFS	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -FS-T <sub>XPR2</sub> , LEU2	This study
PYLβA1	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A1-T <sub>XPR2</sub> , LEU2	This study

Plasmid	Features	Reference
PYLβA2	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A2-T <sub>XPR2</sub> , LEU2	This study
pYLβHS	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HS-T <sub>XPR2</sub> , LEU2	This study
pYLβHR	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , LEU2	This study
pYLβMK	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -MK-T <sub>XPR2</sub> , LEU2	This study
pYLβPK	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PK-T <sub>XPR2</sub> , LEU2	This study
pYLβPD	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PD-T <sub>XPR2</sub> , LEU2	This study
pYLβIDI	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -IDI-T <sub>XPR2</sub> , LEU2	This study
pYLβGS	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -GS-T <sub>XPR2</sub> , LEU2	This study
pYLβFS	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -FS-T <sub>XPR2</sub> , LEU2	This study
pYLγA1	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A1-T <sub>XPR2</sub> , LEU2	This study
PYLγA2	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -A2-T <sub>XPR2</sub> , LEU2	This study
pYLγHS	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HS-T <sub>XPR2</sub> , LEU2	This study
pYLγHR	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , LEU2	This study
pYLγMK	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -MK-T <sub>XPR2</sub> , LEU2	This study
pYLγPK	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PK-T <sub>XPR2</sub> , LEU2	This study
pYLγPD	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -PD-T <sub>XPR2</sub> , LEU2	This study
pYLγIDI	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -IDI-T <sub>XPR2</sub> , LEU2	This study
pYLγGS	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -GS-T <sub>XPR2</sub> , LEU2	This study
pYLγFS	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -FS-T <sub>XPR2</sub> , LEU2	This study
pYLαHR-Acrb	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -Acrb-T <sub>XPR2</sub> , LEU2	This study
pYLαHR-CMQ	P <sub>hp4d</sub> -αBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -CMQ-T <sub>XPR2</sub> , LEU2	This study
pYLβHR-Acrb	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -Acrb-T <sub>XPR2</sub> , LEU2	This study
pYLβHR-CMQ	P <sub>hp4d</sub> -βBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -CMQ-T <sub>XPR2</sub> , LEU2	This study
pYLγHR-Acrb	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -Acrb-T <sub>XPR2</sub> , LEU2	This study
pYLγHR-CMQ	P <sub>hp4d</sub> -γBS-T <sub>XPR2</sub> , P <sub>hp4d</sub> -HR-T <sub>XPR2</sub> , P <sub>hp4d</sub> -CMQ-T <sub>XPR2</sub> , LEU2	This study

## 4.1. Strains, vectors and culture conditions

*Y. lipolytica* Po1g KU70Δ was used as the base strain in this study. Routine cultivation of *Y. lipolytica* strains was carried out at 30 °C in YPD medium. *E. coli* DH5α was used for plasmid construction and amplification and *E. coli* strains were routinely cultured in LB medium supplemented with 100 μg/mL of ampicillin at 37 °C. The yeast extract peptone dextrose (YPD) medium (20 g/L glucose, 20 g/L peptone, and 10 g/L yeast extract) was used for strain activation, whereas the yeast synthetic complete (YNB) (6.7 g/L yeast nitrogen base without amino acids, 20 g/L glucose, 15 g/L Bacto agar) lacking the appropriate nutrients was used for the screening of transformants.

## 4.2. Plasmids construction and yeast transformation

The α-bisabolene synthase gene (*αBS*, GenBank ID: AF006195.1) from *A. grandis*, and β-bisabolene synthase gene (*βBs*, GenBank ID: AB511914.1) from *Z. officinale* and γ-bisabolene synthase gene (*γBS*, GenBank ID: KU674381.1) from *H. annuus* were synthesized and codon-optimized by Genewiz (Jiangsu, China). The genes *αBS*, *βBs* and *γBS* were cloned into pYLEX1 with primers α-F/α-R, β-F/β-R and γ-F/γ-R (Additional file 1: Table S2) to yield plasmid pYLaBS, pYLβBS and pYLyBS, respectively. The genes *ACOAT1*, *ACOAT2*, *HMGS*, *HMGR*, *MK*, *PMK*, *PMVADO*, *IPPDI*, *GGPPS*, and *FPPS* were cloned into pYLEX1 with primers *ACOAT1-F/ACOAT1-R*, *ACOAT2-F/ACOAT2-R*, *HMGS-F/HMGS-R*, *HMGR-F/HMGR-R*, *MK-F/MK-R*, *PMK-F/PMK-R*, *PMVADO-F/PMVADO-R*, *IPPDI-F/IPPDI-R*, *GGPPS-F/GGPPS-R*, *FPPS-F/FPPS-R* to yield plasmid pYLA1, pYLA2, pYLHS, pYLHR, pYLMK, pYLPK, pYLPD, pYLIDI, pYLGS and pYLFS, respectively. The expression cassettes of *ACOAT1*, *ACOAT2*, *HMGS*, *HMGR*, *MK*, *PMK*, *PMVADO*, *IPPDI*, *GGPPS* and *FPPS* were cloned into pYLaBS, pYLβBS and pYLyBS with primers *BDH-F/BDH-R* to yield plasmid pYLaA1, pYLaA2, pYLaHS, pYLaHR, pYLaMK, pYLaPK, pYLaPD, pYLaIDI, pYLaGS, pYLaFS, pYLβA1, pYLβA2, pYLβHS, pYLβHR, pYLβMK, pYLβPK, pYLβPD, pYLβIDI, pYLβGS, pYLβFS, pYLyA1, pYLyA2, pYLyHS, pYLyHR, pYLyMK, pYLyPK, pYLyPD, pYLyIDI, pYLyGS and pYLyFS, respectively.

The AcrB efflux pump gene from *E. coli* and the ABC-G1 efflux pump gene from *G. clavigera* were synthesized and codon-optimized by Genewiz (Jiangsu, China). The expression cassettes of AcrB and ABC-G1 were cloned into pYLaHR, pYLβHR, pYLyHR with primers *Acrb-BDH-F/Acrb-BDH-R* and *CMQ-BDH-F/CMQ-BDH-R* to yield plasmid pYLaHR-Acrb, pYLβHR-Acrb, pYLyHR-Acrb, pYLaHR-CMQ, pYLβHR-CMQ, pYLyHR-CMQ, respectively. All plasmids were first linearized with Spe I and then transformed into competent cells of *Y. lipolytica* strains using the lithium acetate/single-stranded carrier DNA/polyethylene glycol method [24].

## 4.3. Strain construction

Yeast colonies of *Y. lipolytica* Po1g KU70Δ were grown in 50 mL of fresh YPD medium for 24 h. Cells were pelleted and washed twice with 20 mL Tris-EDTA (TE) buffer (10 mM Tris, 1 mM EDTA, pH 7.5) and once with 0.1 M lithium acetate (pH 6.0). Then resuspend the cell with 5 mL of 0.1 M lithium acetate (pH 6.0), and incubate for 10 min at room temperature and aliquot 100 μL into sterile 2 mL tubes. The competent cells were then mixed by vortexing with 0.7 mL of 40% PEG-4000, 10 μL of denatured salmon sperm DNA and 10 μL of linearized recombination plasmids for 1 h. The transformation mixture and incubated at 39 °C for 1 h. Then add 1 mL YPD medium and recover for 2 h at 30 °C and 225 rpm. Following that, the transformation mixture was pelleted, resuspended in water and plated directly onto YNB plates. After selection, the following engineered *Y. lipolytica* strains were generated: Po1g KaBS, Po1g KβBS, Po1g KyBS, Po1g KaA1, Po1g KaA2, Po1g KaHS, Po1g KaHR, Po1g KaMK, Po1g KaPK, Po1g KaPD, Po1g KaIDI, Po1g KaGS, Po1g KaFS, Po1g KβA1, Po1g KβA2, Po1g KβHS, Po1g KβHR, Po1g KβMK, Po1g KβPK, Po1g KβPD, Po1g KβIDI, Po1g KβGS, Po1g KβFS, Po1g KyA1, Po1g KyA2, Po1g KyHS, Po1g KyHR, Po1g KyMK, Po1g KyPK, Po1g KyPD, Po1g KyIDI, Po1g KyGS, Po1g KyFS, Po1g KaHR-Acrb, Po1g KaHR-CMQ, Po1g KβHR-Acrb, Po1g KβHR-CMQ, Po1g KyHR-Acrb, Po1g KyHR-CMQ (Table 3).

Table 3  
Strains used in this study

Strains	Genotype	Reference
Po1g KU70Δ	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-	[24]
Po1g KαBS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS	This study
Po1g KβBS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS	This study
Po1g KγBS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, γBS	This study
Po1g KαA1	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, ACOAAT1	This study
Po1g KαA2	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, ACOAAT2	This study
Po1g KαHS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, HMGS	This study
Po1g KαHR	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, HMGR	This study
Po1g KαMK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, MK	This study
Po1g KαPK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, PMK	This study
Po1g KαPD	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, PMVADO	This study
Po1g KαIDI	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, IPPDI	This study
Po1g KαGS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, GGPPS	This study
Po1g KαFS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, FPPS	This study
Po1g KβA1	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, ACOAAT1	This study
Po1g KβA2	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, ACOAAT2	This study
Po1g KβHS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, HMGS	This study
Po1g KβHR	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, HMGR	This study
Po1g KβMK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, MK	This study
Po1g KβPK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, PMK	This study
Po1g KβPD	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, PMVADO	This study
Po1g KβIDI	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, IPPDI	This study
Po1g KβGS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, GGPPS	This study
Po1g KβFS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-, βBS, FPPS	This study
Po1g KγA1	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, ACOAAT1	This study
Po1g KγA2	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, ACOAAT2	This study
Po1g KγHS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, HMGS	This study
Po1g KγHR	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, HMGR	This study
Po1g KγMK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70-αBS, MK	This study



Strains	Genotype	Reference
Po1g KyPK	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, PMK	This study
Po1g KyPD	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, PMVADO	This study
Po1g KyIDI	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, IPPDI	This study
Po1g KyGS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, GGPPS	This study
Po1g KyFS	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, FPPS	This study
Po1g K $\alpha$ HR-Acrb	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, HMGR, Acrb	This study
Po1g K $\alpha$ HR-CMQ	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, HMGR, CMQ	This study
Po1g K $\beta$ HR-Acrb	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\beta$ BS, HMGR, Acrb	This study
Po1g K $\beta$ HR-CMQ	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\beta$ BS, HMGR, CMQ	This study
Po1g K $\gamma$ HR-Acrb	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, HMGR, Acrb	This study
Po1g K $\gamma$ HR-CMQ	MatA, leu2-270, ura3-302::URA3, xpr2-332, axp-2, ku70- $\alpha$ BS, HMGR, CMQ	This study

#### 4.4. Culturing the engineered *Y. lipolytica* strains for $\alpha$ -bisabolene, $\beta$ -bisabolene and $\gamma$ -bisabolene production

To produce  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene, seed cultures were prepared by inoculating 5 mL of YPD medium in the 20-mL culture tubes with the engineered *Y. lipolytica* strains. The cells were grown at 30 °C for 24 h with agitation. Following that, 250-mL flasks containing 25 mL of YPD medium were inoculated to OD<sub>600</sub> 0.1 with the seed cultures. All cultures were shaken at 200 rpm and 30 °C. To avoid loss of bisabolene during cultivation, 10% of *n*-dodecane overlay was added into the YPD medium prior to cultivation. Samples were then collected at day 5. In order to further increase the yield of  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene, 1.18% WCO was added to the YPD medium as a carbon source to replace glucose with the same carbon number. Using the optimum fermentation parameters determined before, 0.2% Mg<sup>2+</sup> was added to the medium, and the *n*-dodecane layer was added into WCO medium before fermentation. At the end of fermentation, the mixture of the *n*-dodecane layer and WCO formed a one-layer system after centrifuging at 7500 rpm for 10 min. Therefore, the upper one-layer organic phase was used for analysis of bisabolene production by GC/MS.

#### 4.5. GC–MS analysis of $\alpha$ -bisabolene, $\beta$ -bisabolene and $\gamma$ -bisabolene produced in the engineered *Y. lipolytica* strains

For the determination of  $\alpha$ -bisabolene,  $\beta$ -bisabolene and  $\gamma$ -bisabolene, all cultures were centrifuged at 7500 rpm for 10 min at each time of sampling. Specially, in the experiments using WCO as the sole carbon source, this volume of organic phase analyzed by GC–MS represents the total volume of WCO and *n*-dodecane. Then, 1  $\mu$ L organic phase was then analyzed by GC–MS using an Agilent 7890A GC with an 5975C MSD equipped with a HP-5MS column (60 m  $\times$  0.25 mm  $\times$  0.25  $\mu$ m, Agilent, Santa Clara, CA, USA). GC oven temperature was initially held at 60 °C for 2 min, and then ramped to 140 °C at a rate of 5 °C/min. It was then subsequently ramped at 5 °C/min to 280 °C and held for 5 min. The split ratio was 10:1. Helium was used as the carrier gas, with an inlet pressure of 13.8 psi. The injector was maintained at 280 °C and the ion source temperature was set to 230 °C. Final data analysis was achieved using Enhanced Data Analysis software (Agilent, Santa Clara, CA, USA).

## Abbreviations

GC/MS: gas chromatography/mass spectrometry; OD<sub>600</sub>: optical density at 600 nm; LB medium: 0.5% yeast extract, 1% tryptone and 1% NaCl; YPD medium: 1% yeast extract, 2% peptone and 2% glucose; WCO medium: 1% yeast extract, 2% peptone and 1.18% WCO; YNB plate: 2% glucose, 0.67% yeast nitrogen base without amino acids and 2% agar; PCR: polymerase chain reaction.

## Declarations

### Ethics approval and consent to participate

This manuscript does not contain any studies with human participants or animals performed by any of the authors.

### Consent for publication

All authors give consent to publish the research in Biotechnology for Biofuels.

### Availability of data and material

All relevant data generated or analyzed during this study were included in this published article.

### Competing interests

The authors declare that they have no competing interests.

### Funding

The Natural Science Foundation of Tianjin, China (17JCYBJC40800), the Research Foundation of Tianjin Municipal Education Commission, China (2017ZD03), the Innovative Research Team of Tianjin Municipal Education Commission, China (TD13-5013), Tianjin Municipal Science and Technology Project (18PTSJJC00140), Startup Fund for “Haihe Young Scholars” of Tianjin University of Science and Technology, the Thousand Young Talents Program of Tianjin, China.

### Authors' contributions

AQY, DGX and CYZ conceived and designed the study. YKZ, KZ, JL, YZ and SLL performed plasmid and strain construction, and fermentation experiments. YKZ and JL wrote the manuscript. AQY, DGX and CYZ revised the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

This work was supported by the Natural Science Foundation of Tianjin, China (17JCYBJC40800), the Research Foundation of Tianjin Municipal Education Commission, China (2017ZD03), the Innovative Research Team of Tianjin Municipal Education Commission, China (TD13-5013), the Startup Fund for “Haihe Young Scholars” of Tianjin University of Science and Technology, the Thousand Young Talents Program of Tianjin, China.

### Authors' information

## References


1. Peralta-Yahya PP, Ouellet M, Chan R, Mukhopadhyay A, Keasling JD, Lee TS. Identification and microbial production of a terpene-based advanced biofuel. *Nat Commun.* 2011;2:483.
2. Davies FK, Work VH, Beliaev AS, Posewitz MC. Engineering limonene and bisabolene production in wild type and a glycogen-deficient mutant of *Synechococcus* sp. PCC 7002. *Front Bioeng Biotechnol.* 2014;2:21.
3. Wang C, Zada B, Wei G, Kim SW. Metabolic engineering and synthetic biology approaches driving isoprenoid production in *Escherichia coli*. *Bioresour Technol.* 2017;241:430–8.
4. Jou YJ, Hua CH, Lin CS, Wang CY, Wan L, Lin YJ, et al. Anticancer activity of  $\gamma$ -bisabolene in human neuroblastoma cells via induction of p53-mediated mitochondrial apoptosis. *Molecules.* 2016;21(5):601.
5. Lopresto CG, Petrillo F, Casazza AA, Aliakbarian B, Perego P, Calabro V. A non-conventional method to extract  $\alpha$ -limonene from waste lemon peels and comparison with traditional Soxhlet extraction. *Sep Purif Technol.* 2014;137:13–20.
6. Liu T, Khosla C. Chemistry. A balancing act for taxol precursor pathways in *E. coli*. *Science.* 2010;330(6000):44–5.
7. Madzak C, Beckerich JM. Heterologous protein expression and secretion in *Yarrowia lipolytica*. In: Barth G, editor. *Yarrowia lipolytica*. Berlin Heidelberg: Springer; 2013. pp. 1–76.
8. Abghari A, Chen S. *Yarrowia lipolytica* as an oleaginous cell factory platform for production of fatty acid-based biofuel and bioproducts. *Font Energy Res.* 2014;2:1–21.
9. Abdel-Mawgoud AM, Markham KA, Palmer CM, Liu N, Stephanopoulos G, Alper HS. Metabolic engineering in the host *Yarrowia lipolytica*. *Metab Eng.* 2018;50:192–208.
10. Beopoulos A, Cescut J, Haddouche R, Uribelarrea JL, Molina-Jouve C, Nicaud JM. *Yarrowia lipolytica* as a model for bio-oil production. *Prog Lipid Res.* 2009;48(6):375–87.
11. Madzak C, Gaillardin C, Beckerich JM. Heterologous protein expression and secretion in the non-conventional yeast *Yarrowia lipolytica*: a review. *J Biotechnol.* 2004;109(1–2):63–81.
12. Cao X, Lv YB, Chen J, Imanaka T, Wei LJ, Hua Q. Metabolic engineering of oleaginous yeast *Yarrowia lipolytica* for limonene overproduction. *Biotechnol Biofuels.* 2016;9:214.
13. Pang Y, Zhao Y, Li S, Zhao Y, Li J, Hu Z, et al. Engineering the oleaginous yeast *Yarrowia lipolytica* to produce limonene from waste cooking oil. *Biotechnol Biofuels.* 2019;12:241.
14. Cao X, Wei LJ, Lin JY, Hua Q. Enhancing linalool production by engineering oleaginous yeast *Yarrowia lipolytica*. *Bioresour Technol.* 2017;245(Pt B):1641–4.
15. Liu Y, Jiang X, Cui Z, Wang Z, Qi Q, Hou J. Engineering the oleaginous yeast *Yarrowia lipolytica* for production of  $\alpha$ -farnesene. *Biotechnol Biofuels.* 2019;12:296.
16. Jin CC, Zhang JL, Song H, Cao YX. Boosting the biosynthesis of betulinic acid and related triterpenoids in *Yarrowia lipolytica* via multimodular metabolic engineering. *Microb Cell Fact.* 2019;18:77.
17. Gao S, Tong Y, Zhu L, Ge M, Jiang Y, Chen D, et al. Production of  $\beta$ -carotene by expressing a heterologous multifunctional carotene synthase in *Yarrowia lipolytica*. *Biotechnol Lett.* 2017;39(6):921–7.

18. Larroude M, Celinska E, Back A, Thomas S, Nicaud JM, Ledesma-Amaro R. A synthetic biology approach to transform *Yarrowia lipolytica* into a competitive biotechnological producer of  $\beta$ -carotene. *Biotechnol Bioeng*. 2017;115(2):464–72.
19. Matthäus F, Ketelhot M, Gatter M, Barth G. Production of lycopene in the non-carotenoid-producing yeast *Yarrowia lipolytica*. *Appl Environ Microbiol*. 2014;80(5):1660–9.
20. Schwartz C, Frogue K, Misa J, Wheeldon I. Host and pathway engineering for enhanced lycopene biosynthesis in *Yarrowia lipolytica*. *Front Microbiol*. 2017;8:2233.
21. Mcandrew R, Peralta-Yahya P, Degiovanni A, Pereira JH, Hadi MZ, Keasling JD, et al. Structure of a three-domain sesquiterpene synthase: a prospective target for advanced biofuels production. *Structure*. 2011;19(12):1876–84.
22. Fujisawa M, Harada H, Kenmoku H, Mizutani S, Misawa N. Cloning and characterization of a novel gene that encodes (S)- $\beta$ -bisabolene synthase from ginger, *Zingiber officinale*. *Planta*. 2010;232(1):121–30.
23. Aschenbrenner AK, Kwon M, Conrad J, Ro DK, Spring O. Identification and characterization of two bisabolene synthases from linear glandular trichomes of sunflower (*Helianthus annuus* L. Asteraceae). *Phytochemistry*. 2016;124:29–37.
24. Yu AQ, Pratomo N, Ng TK, Ling H, Cho HS, Leong SSJ, et al. Genetic engineering of an unconventional yeast for renewable biofuel and biochemical production. *J Vis Exp*. 2016;115:e54371.
25. Chappell J, Vonlancken C, Vögeli U. Elicitor-inducible 3-hydroxy-3-methylglutaryl coenzyme a reductase activity is required for sesquiterpene accumulation in *tobacco* cell suspension cultures. *Plant Physiol*. 1991;97(2):693–8.
26. Chappell J, Wolf F, Proulx J, Cuellar R, Saunders C. Is the reaction catalyzed by 3-hydroxy-3-methylglutaryl coenzyme a reductase a rate-limiting step for isoprenoid biosynthesis in plants? *Plant Physiol*. 1995;109(4):1337–43.
27. Hampton R, Dimster-Denk D, Rine J. The biology of HMG-CoA reductase: the pros of contra-regulation. *Trends Biochem Sci*. 1996;21(4):140–5.
28. Chappell J, Nable R. Induction of sesquiterpenoid biosynthesis in *tobacco* cell suspension cultures by fungal elicitor 1. *Plant Physiol*. 1987;85(2):469–73.
29. Stermer BA, Bostock RM. Involvement of 3-hydroxy-3-methylglutaryl coenzyme a reductase in the regulation of sesquiterpenoid phytoalexin synthesis in *potato*. *Plant Physiol*. 1987;84(2):404–8.
30. Parveen M, Hasan MK, Takahashi J, Murata Y, Kitagawa E, Kodama O, et al. Response of *Saccharomyces cerevisiae* to a monoterpene: evaluation of antifungal potential by DNA microarray analysis. *J Antimicrob Chemother*. 2004;54(1):46–55.
31. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils—a review. *Food Chem Toxicol*. 2008;46(2):446–75.
32. Witzke S, Duelund L, Kongsted J, Petersen M, Mouritsen OG, Khandelia H. Inclusion of terpenoid plant extracts in lipid bilayers investigated by molecular dynamics simulations. *J Phy Chem B*. 2010;114(48):15825–31.
33. Soylu EM, Soylu S, Kurt S. Antimicrobial activities of the essential oils of various plants against tomato late blight disease agent *Phytophthora infestans*. *Mycopathologia*. 2006;161(2):119–28.
34. Alper H, Moxley J, Nevoigt E, Fink GR, Stephanopoulos G. Engineering yeast transcription machinery for improved ethanol tolerance and production. *Science*. 2006;314(5805):1565–8.

35. Jarboe LR, Grabar TB, Yomano LP, Shanmugan KT, Ingram LO. Development of ethanologenic bacteria. *Adv Biochem Eng Biot.* 2007;108:237–61.
36. Foo JL, Jensen HM, Dahl RH, George K, Keasling JD, Lee TK, et al. Improving microbial biogasoline production in *Escherichia coli* using tolerance engineering. *mBio.* 2014;5(6):e01932.
37. Foo JL, Leong SSJ. Directed evolution of an *E. coli* inner membrane transporter for improved efflux of biofuel molecules. *Biotechnol Biofuels.* 2013;6:81.
38. Yoo HW, Kim J, Patil MD, Park BG, Joo SY, Yun H, et al. Production of 12-hydroxy dodecanoic acid methyl ester using a signal peptide sequence-optimized transporter AlkL and a novel monooxygenase. *Bioresour Technol.* 2019;291:121812.
39. Poole K. Multidrug efflux pumps and antimicrobial resistance in *Pseudomonas aeruginosa* and related organisms. *J Mol Microbiol Biotechnol.* 2001;3(2):255–64.
40. Wang JF, Xiong ZQ, Li SY, Wang Y. Enhancing isoprenoid production through systematically assembling and modulating efflux pumps in *Escherichia coli*. *Appl Microbiol Biotechnol.* 2013;97(18):8057–67.
41. Dunlop MJ, Dossani ZY, Szmids H, Chu HC, Lee TK, Keasling JD, et al. Engineering microbial biofuel tolerance and export using efflux pumps. *Mol Syst Biol.* 2011;7:487.
42. Isken S, de Bont JA. Bacteria tolerant to organic solvents. *Extremophiles.* 1998;2(3):229–38.
43. Ramos JL, Duque E, Gallegos MT, Godoy P, Ramos-Gonzalez MI, Rojas A, et al. Mechanisms of solvent tolerance in gram-negative bacteria. *Annu Rev Microbiol.* 2002;56:743–68.
44. Putman M, Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. *Microbiol Mol Biol Rev.* 2000;64:672–93.
45. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. *Biochim et Biophys Acta.* 2009;1794:769–81.
46. Higgins CF. ABC transporters: From microorganisms to man. *Annu Rev Cell Biol.* 1992;8:67–113.
47. Rees DC, Johnson E, Lewinson O. ABC transporters: The power to change. *Nat Rev Mol Cell Biol.* 2009;10(3):218–27.
48. Pohl A, Devaux PF, Herrmann A. Function of prokaryotic and eukaryotic ABC proteins in lipid transport. *Biochim Biophys Acta.* 2005;1733(1):29–52.
49. Wang Y, Lim L, DiGuistini S, Robertson G, Bohlmann J, Breuil C. A specialized ABC efflux transporter GcABC-G1 confers monoterpene resistance to *Grosmannia clavigera*, a bark beetle-associated fungal pathogen of pine trees. *New Phytol.* 2013;197(3):886–98.
50. Maddikeri GL, Pandit AB, Gogate PR. Intensification approaches for biodiesel synthesis from waste cooking oil: a review. *Ind Eng Chem Res.* 2012;51(45):14610–28.
51. Lisboa P, Rodrigues AR, Martin JL, Simoes P, Barreiros S, Paiva A. Economic analysis of a plant for biodiesel production from waste cooking oil via enzymatic transesterification using supercritical carbon dioxide. *J Supercrit Fluids.* 2014;5:31–40.
52. Lam SS, Liew RK, Jusoh A, Chong CT, Ani FN, Chase HA. Progress in waste oil to sustainable energy, with emphasis on pyrolysis techniques. *Renew Sust Energy Rev.* 2016;53:741–53.
53. Moftah OAS, Grbavcic SZ, Moftah WAS, Lukovic ND, Prodanovic OL, Jakovetic SM, et al. Lipase production by *Yarrowia lipolytica* using olive oil processing wastes as substrates. *J Chem Soc.* 2013;78(6):781–94.

54. Ferreira P, Lopes M, Mota M, Belo I. Oxygen mass transfer impact on citric acid production by *Yarrowia lipolytica* from crude glycerol. *Biochem Eng J.* 2016;110:35–42.
55. Xiang QS, Yue TL, Yuan YH, Gao ZP, Wang H, Wang S. Effects of metal ions on growth of *Streptomyces gilvosporeus* and biosynthesis of natamycin. *J Northwest Univer.* 2010;(38):209–14(in Chinese).
56. Zhao T, Gao SH, Chen CH, Ye RF, Zhang ZH, Li Q, et al. Effects and mechanism analysis of metal ions on biosynthesis and component transformation of erythromycin. *Chinese J of Antibio.* 2013;(38):507–11(in Chinese).
57. Jernejc K, Legisa M. The influence of metal ions on malic enzyme activity and lipid synthesis in *Aspergillus niger*. *FEMS Microbiol Lett.* 2002;217(2):185–90.
58. Kim EM, Min Woo H, Tian T, Yilmaz S, Javidpour P, Keasling JD, et al. Autonomous control of metabolic state by a quorum sensing (QS)-mediated regulator for bisabolene production in engineered *E. coli*. *Metab Eng.* 2017;44:325–36.
59. Sebesta J, Peebles CA. Improving heterologous protein expression in *Synechocystis* sp. PCC 6803 for alpha-bisabolene production. *Metab Eng Commun.* 2019;10:e00117.
60. Wichmann J, Baier T, Wentnagel E, Lauersen KJ, Kruse O. Tailored carbon partitioning for phototrophic production of (E)- $\alpha$ -bisabolene from the green microalga *Chlamydomonas reinhardtii*. *Metab Eng.* 2017;45:211.
61. Yaegashi J, Kirby J, Ito M, Sun J, Dutta T, Mirsiaghi M, et al. *Rhodospiridium toruloides*: a new platform organism for conversion of lignocellulose into terpene biofuels and bioproducts. *Biotechnol Biofuels.* 2017;10:241.
62. Strong hybrid promoters and  
Madzak C, Treton B, Blanchin-Roland S. Strong hybrid promoters and.
63. integrative expression/secretion. vectors for quasi-constitutive expression of heterologous proteins in the yeast *Yarrowia lipolytica*. *J Mol Microbiol Biotechnol.* 2000;2(2):207–16.


## Figures



**Figure 1**

Biosynthesis pathway for bisabolene production in the yeast *Y. lipolytica* and biosynthesis pathway for bisabolene production in the plants. Bisabolene is biosynthesized from the precursor FPP by enzymatic biotransformation with  $\alpha$ -,  $\beta$ -,  $\gamma$ -bisabolene synthetase. Biosynthesis pathway for bisabolene production in *Y. lipolytica*. Yeast rely on the mevalonate pathway to produce FPP from acetyl-CoA. Since the bisabolene synthase (BS) is not present in *Y. lipolytica*, to construct a complete bisabolene pathway in *Y. lipolytica*, three heterologous genes encoding  $\alpha$ -bisabolene synthase ( $\alpha$ BS, from *A. grandis*) and  $\beta$ -bisabolene synthase gene ( $\beta$ BS, from *Z. officinale*) and the  $\gamma$ -bisabolene synthase gene ( $\gamma$ BS, from *H. annuus*) were introduced (shown in purple). The endogenous MVA pathway enzymes (shown in red) that were overexpressed in the engineered *Y. lipolytica* strains. Enzymes involved in the MVA pathway in *Y. lipolytica* are shown in parentheses. Homologous enzymes found in *Y. lipolytica* are shown in red. DXS: DXP synthase, DXR: DXP-reductoisomerase, CMS: MEP cytidyltransferase, CMK: CDP-ME kinase, MCS: MECDP-synthase, HDS: (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase, HDR: HMBPP reductase, IPPDI: isopentenyl-diphosphate delta-isomerase, GGPPS: geranyl-diphosphate synthase,  $\alpha$ BS:  $\alpha$ -bisabolene synthase,  $\beta$ BS:  $\beta$ -bisabolene synthase,  $\gamma$ BS:  $\gamma$ -bisabolene synthase ACOAT1: acetyl-CoA C-acetyltransferase 1, ACOAT2: acetyl-CoA C-acetyltransferase 2, HMGS: hydroxymethylglutaryl-CoA synthase, HMGR: hydroxymethylglutaryl-CoA reductase, MK: mevalonate kinase, PMK: phosphomevalonate kinase, PMVADO: diphosphomevalonate decarboxylase, IPPDI: isopentenyl-diphosphate delta-isomerase, GGPPS: geranylgeranyl diphosphate synthase, type III, FPPS: farnesyl diphosphate synthase. **b** Biosynthesis pathway for bisabolene production in plants. Plants produce FPP via the methylerythritol phosphate pathway from pyruvate and glyceraldehyde-3-phosphate. The endogenous MEP pathway enzymes are shown in red. DXS: DXP synthase, DXR: DXP-reductoisomerase, CMS: MEP cytidyltransferase, CMK: CDP-ME kinase, MCS: MECDP-synthase, HDS: (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase, HDR: HMBPP reductase, IPPDI: isopentenyl-diphosphate


delta-isomerase, GPPS: geranyl-diphosphate synthase,  $\alpha$ BS:  $\alpha$ -bisabolene synthase,  $\beta$ BS:  $\beta$ -bisabolene synthase,  $\gamma$ BS:  $\gamma$ -bisabolene synthase.



**Figure 2**


Effects of single-gene overexpression of genes involved in the MVA pathway on  $\alpha$ -bisabolene production. Effects of single-gene overexpression of genes involved in the MVA pathway on  $\alpha$ -bisabolene production. Ten genes including ACOAAT1, ACOAAT2, HMGS, HMGR, MK, PMK, PMVADO, IPPDI, GGPPS and FPPS involved in MVA pathway were overexpressed individually with  $\alpha$ -bisabolene synthase. Bars represent bisabolene titers.






**Figure 3**

Effects of single-gene overexpression of genes involved in the MVA pathway on  $\beta$ -bisabolene production. Effects of single-gene overexpression of genes involved in the MVA pathway on  $\beta$ -bisabolene production. Ten genes including ACOAAT1, ACOAAT2, HMGS, HMGR, MK, PMK, PMVADO, IPPDI, GGPPS and FPPS involved in MVA pathway were overexpressed individually with  $\beta$ -bisabolene synthase. Bars represent bisabolene titers.




**Figure 4**

Effects of single-gene overexpression of genes involved in the MVA pathway on  $\gamma$ -bisabolene production. Effects of single-gene overexpression of genes involved in the MVA pathway on  $\gamma$ -bisabolene production. Ten genes including ACOAAT1, ACOAAT2, HMGS, HMGR, MK, PMK, PMVADO, IPPDI, GGPPS and FPPS involved in MVA pathway were overexpressed individually with  $\gamma$ -bisabolene synthase. Bars represent bisabolene titers.




**Figure 5**

Effect of efflux pump and magnesium ion addition on  $\alpha$ -bisabolene, accumulation during cultures on WCO Effect of efflux pump on  $\alpha$ -bisabolene and magnesium ion addition on  $\alpha$ -bisabolene accumulation. The cultivation was performed at 200 rpm with an initial OD<sub>600</sub> of 0.1 and 10% of n-dodecane in 50 mL of liquid WCO medium in a 250-mL shake flask for 5 days. Bars represent bisabolene yields and lines represent gene expression improvements over controls. Plasmid maps of constructs containing gene integration cassettes used in this study. The strain all-Acrb carries the codon-optimized genes of  $\alpha$ -BS,  $\beta$ -BS or  $\gamma$ -BS and HMGR gene and Acrb gene. The strain all-ABCG1 carries the codon-optimized genes of  $\alpha$ -BS,  $\beta$ -BS or  $\gamma$ -BS and HMGR gene and ABCG1 gene.



**Figure 6**

Effect of efflux pump and magnesium ion addition on  $\beta$ -bisabolene accumulation during cultures on WCO Effect of efflux pump on  $\beta$ -bisabolene and magnesium ion addition on  $\beta$ -bisabolene accumulation. The cultivation was performed at 200 rpm with an initial OD600 of 0.1 and 10% of n-dodecane in 50 mL of liquid WCO medium in a 250-mL shake flask for 5 days. Bars represent bisabolene titers and lines represent gene expression improvements over controls.



**Figure 7**

Effect of efflux pump and magnesium ion addition on  $\gamma$ -bisabolene accumulation during cultures on WCO Effect of efflux pump on  $\gamma$ -bisabolene and magnesium ion addition on  $\gamma$ -bisabolene accumulation. The cultivation was performed at 200 rpm with an initial OD600 of 0.1 and 10% of n-dodecane in 50 mL of liquid WCO medium in a 250-mL shake flask for 5 days. Bars represent bisabolene titers and lines represent gene expression improvements over controls.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalfileforBforB.docx](#)